Clinical Trial: Bisphosphonate Treatment of Osteogenesis Imperfecta
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Bisphosphonate Treatment of Osteogenesis Imperfecta
Brief Summary: The primary purpose of this trial is to evaluate whether the investigational medication is safe, effective and has the ability to increase spine bone density in osteogenesis imperfecta (OI) patients.
Detailed Summary:
Sponsor: Novartis Pharmaceuticals
Current Primary Outcome: Change in lumbar spine bone mineral density at month 12 relative to baseline
Original Primary Outcome:
Current Secondary Outcome: Change in Z score of the lumbar spine at month 12 relative to baseline
Original Secondary Outcome:
Information By: Novartis
Dates:
Date Received: June 27, 2003
Date Started: June 2003
Date Completion:
Last Updated: November 16, 2016
Last Verified: November 2016